NBIX
NASDAQ · Biotechnology
Neurocrine Biosciences Inc
$164.63
+4.87 (+3.05%)
Performance
1D
—
1W
+13.26%
1M
+15.58%
3M
-0.18%
6M
+5.67%
1Y
+9.74%
YTD
+17.09%
Open$159.98
Previous Close$159.76
Day High$165.86
Day Low$158.66
52W High$186.12
52W Low$122.14
Volume—
Avg Volume1.63M
Market Cap16.41B
P/E Ratio23.26
EPS$6.82
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$147.22
Above
SMA 200
$148.02
Above
RSI (14)
80.2
Overbought
Trend
Death Cross
Bearish
Analyst Ratings
Strong Buy
37 analysts
Price Target
-22.9% upside
Current
$164.63
$164.63
Target
$126.93
$126.93
$104.30
$126.93 avg
$177.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.78B | 2.24B | 5.53B |
| Net Income | 465.46M | 336.96M | 497.45M |
| Profit Margin | 16.7% | 15.9% | 9.0% |
| EBITDA | 627.39M | 479.42M | 909.27M |
| Free Cash Flow | — | — | 422.12M |
| Rev Growth | +24.3% | +24.3% | -8.7% |
| Debt/Equity | — | — | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |